Hexima Ltd (AU:HXL)
ASX:HXL
Want to see AU:HXL full AI Analyst Report?
Top Page
Hexima Ltd
(Sydney:HXL)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.05
▲(410.00% Upside)
Action:UpgradedDate:04/23/26
The score is held down primarily by weak financial performance (ongoing losses, negligible recent revenue, and continued cash burn) and an unfavorable valuation signal (negative P/E). Technicals provide some support due to strong momentum versus moving averages, but the extremely overbought RSI tempers that positive.
Positive Factors
Platform R&D Focus
Hexima’s peptide-based antifungal and antimicrobial R&D, centered on plant defensins, represents a platform strategy addressing structural infectious-disease needs. Platform-driven pipelines create durable optionality across programs and sustain long-term value if clinical progress continues.
Negative Factors
Persistent Losses
The firm remains consistently loss-making with virtually no revenue in recent years, signaling weak commercialization momentum. Over the medium term, absence of recurring revenue means continued reliance on R&D outcomes or external deals to create sustainable cash flows, a high-risk dependency.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform R&D Focus
Hexima’s peptide-based antifungal and antimicrobial R&D, centered on plant defensins, represents a platform strategy addressing structural infectious-disease needs. Platform-driven pipelines create durable optionality across programs and sustain long-term value if clinical progress continues.
Read all positive factors
Hexima Ltd (HXL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.17M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-0.46
Revenue GrowthN/A
EPS Growth75.44%
CountryAU
EmployeesN/A
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding41,759,907
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)AU$47.10M
Hexima Ltd Business Overview & Revenue Model
Company Description
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is the plant defensin, pezadeftide, which is in phase...
How the Company Makes Money
null...
Hexima Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 1.48M | 5.81M | 4.08M |
| Gross Profit | 0.00 | 0.00 | 1.47M | 5.67M | 3.93M |
| EBITDA | 0.00 | -995.54K | -3.08M | -15.21M | -10.34M |
| Net Income | -503.83K | -933.87K | -1.92M | -10.02M | -6.87M |
Balance Sheet | |||||
| Total Assets | 1.56M | 2.27M | 2.96M | 10.75M | 8.58M |
| Cash, Cash Equivalents and Short-Term Investments | 1.54M | 2.23M | 2.19M | 3.96M | 3.42M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 32.00K |
| Total Liabilities | 40.70K | 248.67K | 174.45K | 6.19M | 5.53M |
| Stockholders Equity | 1.52M | 2.02M | 2.78M | 4.57M | 3.05M |
Cash Flow | |||||
| Free Cash Flow | -637.19K | -161.90K | -1.76M | -9.76M | -5.79M |
| Operating Cash Flow | -637.19K | -161.90K | -1.76M | -9.76M | -5.79M |
| Investing Cash Flow | 46.79K | 98.00K | 38.97K | -1.80K | -903.00 |
| Financing Cash Flow | -100.00K | 100.00K | -3.66K | 10.34M | 7.90M |
Hexima Ltd Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Neutral
100.00
Negative
-150.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HXL, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of -150.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HXL.
Hexima Ltd Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
49 Neutral | AU$44.08M | -6.66 | -370.40% | ― | 9.28% | -40.00% | |
47 Neutral | AU$6.68M | -3.28 | 265.12% | ― | ― | 37.88% | |
47 Neutral | AU$12.30M | -1.00 | -218.76% | ― | 76.94% | 42.95% | |
45 Neutral | AU$2.17M | -1.08 | -32.19% | ― | ― | 75.44% | |
44 Neutral | AU$12.75M | -0.48 | 1068.18% | ― | ― | 40.85% | |
40 Underperform | AU$2.84M | -1.64 | -109.45% | ― | ― | 43.14% |
* Financial Sector Average
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
AU:VBS
Vectus Biosystems Limited
0.13
0.05
56.25%
AU:CMB
Regeneus Ltd.
0.45
0.22
95.65%
AU:AVE
Avecho Biotechnology Limited
0.01
<0.01
20.00%
AU:1AD
AdAlta Ltd.
―
―
―
AU:ANR
Anatara Lifesciences Ltd
0.01
>-0.01
-9.09%
Hexima Ltd Corporate Events
Hexima Clears Approval Condition for Cash Return of Capital
Apr 16, 2026
Hexima Limited has notified the ASX of an updated cash return of capital for its fully paid ordinary shares, confirming that a key approval condition has now been satisfied. The updated filing, lodged on 16 April 2026, formalises the company’...
Hexima Secures Shareholder Approval for Security Reorganisation
Apr 16, 2026
Hexima Limited has confirmed that a planned consolidation or split of its ordinary fully paid shares, trading under the ASX code HXL, will proceed following shareholder approval. The company updated its earlier March 13, 2026 notice on April 16, 2...
Hexima shareholders back return of capital in decisive vote
Apr 16, 2026
Hexima shareholders have approved a return of capital at a general meeting held on 16 April 2026, with the resolution passed as an ordinary resolution following a poll. The proposal received overwhelming support, with virtually all votes cast in f...
Hexima to Consolidate Ordinary Shares Following Shareholder Approval
Mar 12, 2026
Hexima Ltd has announced a consolidation of its ordinary fully paid shares on the ASX, affecting its HXL security. The measure follows receipt of shareholder approval and is part of a formal reorganisation of the company’s capital structure....
Hexima announces cash return of capital to shareholders
Mar 12, 2026
Hexima Limited has notified the ASX of a proposed cash return of capital to holders of its fully paid ordinary shares under code HXL. The announcement, lodged on 13 March 2026, initiates the formal corporate action process for returning capital to...
Hexima Sets April Vote on $1 Million Capital Return and Share Cancellation
Mar 12, 2026
Hexima Limited has called a general meeting for 16 April 2026 to seek shareholder approval for a return of capital of approximately $1.0 million and a concurrent share cancellation. The proposal would distribute $0.006 per share to shareholders on...
Hexima Narrows Half-Year Loss but Maintains Capital-Conserving Stance
Feb 26, 2026
Hexima Limited has reported a significantly reduced loss for the half-year ended 31 December 2025, with the loss after tax falling 68% to $128,570 compared with the prior corresponding period. Net tangible assets per share declined to 0.83 cents f...
Hexima Preserves $1.4m Cash as It Weighs Capital Return to Shareholders
Jan 29, 2026
Hexima Limited reported a cash balance of $1.4 million at 31 December 2025 and minimal quarterly net operating cash outflows of $38,000, primarily related to compliance and professional fees, as the company remains largely inactive operationally. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.